Hatice KARAOĞLU ASRAK, Nurşen BELET, Özlem TÜFEKÇİ, Canan ÖZLÜ, Birsen BAYSAL, DİLEK İNCE

Investigating the risk factors for antibiotic lock therapy failure in pediatric cancer: a single center retrospective analysis

Background. Catheter-related bloodstream infection (CRBSI) is one of the most common complications of central lines. Data concerning the effectiveness and safety of antibiotic lock therapy (ALT), especially in pediatric hematology and oncology patients, have not yet reached sufficient levels of evidence. We aimed to share our center’s experience on ALT in pediatric cancer and to investigate the causes of ALT failure. Methods. All cases with CRBSI and treated with ALT administiration in children with cancer between January 2015 and May 2019 were reviewed. Patients characteristics, laboratory and clinical findings, treatments, outcome of ALT, recurrences and reinfections were recorded. Patients with successful and unsuccessful ALT outcomes were compared in order to identify the risk factors for ALT failure. Results. Sixteen eligible CRBSI treated with adjunctive ALT were identified. The most common pathogens were coagulase negative staphylococci (8/16, 50%). Treatment failure was observed in 31.2% (5/16). Younger age alone was an independent risk factor for treatment failure (0.9 vs 6.8 years, p = 0.038). Recurrence and reinfection rates were 23.1% and 16.7%. Mild bleeding occured in two cases (12.5%) and occlusion causing catheter removal was seen in one (6.3%). Conclusions. ALT was found to be a safe modality with a success rate of 68.8% in children with cancer at our center and younger age was an independent risk factor for treatment failure. Future studies with larger sample sizes are needed to determine the factors affecting the ALT outcome, especially in childhood malignancies.

PDF

___

1. Mirro J Jr, Rao BN, Stokes DC, et al. A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. J Clin Oncol 1989; 7: 214-222.

2. Wilson MZ, Rafferty C, Deeter D, Comito MA, Hollenbeak CS. Attributable costs of central lineassociated bloodstream infections in a pediatric hematology/oncology population. Am J Infect Control 2014; 42: 1157-1160.

3. Wolf J, Connell TG, Allison KJ, et al. Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infect Dis 2018; 18: 854-863.

4. Karagiannidou S, Zaoutis T, Maniadakis N, Papaevangelou V, Kourlaba G. Attributable length of stay and cost for pediatric and neonatal central line-associated bloodstream infections in Greece. J Infect Public Health 2019; 12: 372-379.

5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.

6. Schoot RA, van Dalen EC, van Ommen CH, van de Wetering MD. Antibiotic and other lock treatments for tunnelled central venous catheterrelated infections in children with cancer. Cochrane Database Syst Rev 2013; 25:CD008975.

7. Norris LB, Kablaoui F, Brilhart MK, Bookstaver PB. Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients. Int J Antimicrob Agents 2017; 50: 308-317.

8. Celebi S, Sezgin ME, Cakır D, et al. Catheterassociated bloodstream infections in pediatric hematology-oncology patients. Pediatr Hematol Oncol 2013; 30: 187-194.

9. Adler A, Yaniv I, Solter E, et al. Catheter-associated bloodstream infections in pediatric hematologyoncology patients: factors associated with catheter removal and recurrence. J Pediatr Hematol Oncol 2006; 28: 23-28.

10. Özdemir H, Karbuz A, Çiftçi E, et al. Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin-lock therapy. Mycoses 2011; 54: e647-e649.

11. Beck O, Muensterer O, Hofmann S, et al. Central venous access devices (CVAD) in pediatric oncology patients-a single-center retrospective study over more than 9 years. Front Pediatr 2019; 7: 260.

12. Hekimoğlu C, Batır E. Ulusal Sağlık Hizmeti İlişkili Enfeksiyonlar Sürveyans Ağı Özet Raporu 2017. Ankara, 2018.

13. Chaudhary M, Bilal MF, Du W, Chu R, Rajpurkar M, McGrath EJ. The impact of ethanol lock therapy on length of stay and catheter salvage in pediatric catheter-associated bloodstream infection. Clin Pediatr (Phila) 2014; 53: 1069-1076.

14. Aygün F, Aygün D, Çokuğraş H, Çam H, Camcıoğlu Y. Çocuk hastalarda kateter ilişkili enfeksiyon sıklığı; bir yıllık deneyim. Çocuk Enfeksiyon Dergisi 2017; 11: 76-81.

15. Pektaş A, Kara A, Gurgey A. Cohort study: Central venous catheter-related complications in children with hematologic diseases at a single center. Turkish J Hematol 2015; 32: 144-151.

16. Del Pozo JL, Alonso M, Serrera A, Hernaez S, Aguinaga A, Leiva J. Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. Diagn Microbiol Infect Dis 2009; 63: 208-212.

17. Nucci M, Anaissie E, Betts RF, et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. Clin Infect Dis 2010; 51: 295-303.

18. Funalleras G, Fernandez-Hidalgo N, Borrego A, et al. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to gramnegative bacilli: a prospective observational study. Clin Infect Dis 2011; 53: e129-e132.

19. Wolf J, Allison KJ, Tang L, Sun Y, Hayden RT, Flynn PM. No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line-related bloodstream infection: results of a retrospective matched cohort study and review of the literature. Pediatr Blood Cancer 2014; 61: 1811- 1815.

20. Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 2005; 55: 90-94.

21. Freire MP, Pierrotti LC, Zerati AE, et al. Role of lock therapy for long-term catheter-related infections by multidrug-resistant bacteria. Antimicrob Agents Chemother 2018; 62: e00569-18.

22. Onder AM, Billings A, Chandar J, et al. PREFABL: Predictors of failure of antibiotic locks for the treatment of catheter-related bacteraemia. Nephrol Dial Transplant 2010; 25: 3686-3693.

23. Chen SH, Yang CP, Jaing TH, Lai JY, Hung IJ. Catheter-related bloodstream infection with removal of catheter in pediatric oncology patients: a 10-year experience in Taiwan. Int J Clin Oncol 2012; 17: 124-130.

24. O’Horo JC, Silva GLM, Safdar N. Anti-infective locks for treatment of central line-associated bloodstream infection: a systematic review and meta-analysis. Am J Nephrol 2011; 34: 415-422.

25. Megged O, Shalit I, Yaniv I, Fisher S, Livni G, Levy I. Outcome of antibiotic lock technique for persistent central venous catheter-associated coagulasenegative Staphylococcus bacteremia in children. Eur J Clin Microbiol Infect Dis 2010; 29: 157-161